---
id: idsa-amr-gram-negative-2024
title: "IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections"
short_title: "IDSA AMR GNR 2024"

organization: Infectious Diseases Society of America
collaborators: null
country: US
url: https://www.idsociety.org/practice-guideline/amr-guidance/
doi: null
pmid: null
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: IDSA Consensus
conditions:
  - antimicrobial resistance
  - ESBL
  - CRE
  - Pseudomonas aeruginosa
  - Acinetobacter baumannii
tags:
  - carbapenems
  - ceftazidime-avibactam
  - meropenem-vaborbactam
  - cefiderocol
  - stewardship

publication_date: 2024-07-12
previous_version_date: 2023-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
Regularly updated IDSA guidance providing expert recommendations for the treatment of specific multi-drug resistant (MDR) gram-negative pathogens, including ESBL-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat (DTR) *Pseudomonas aeruginosa*.

## Key Recommendations

### ESBL-Producing Enterobacterales
- **Preferred Agent**: Carbapenems (ertapenem, meropenem, or imipenem-cilastatin) are preferred for the treatment of serious infections (e.g., bloodstream, pneumonia).
- **Cystitis**: Nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin are preferred for uncomplicated cystitis.
- **Piperacillin-Tazobactam**: Generally discouraged for serious ESBL infections even if susceptible *in vitro*.

### Carbapenem-Resistant Enterobacterales (CRE)
- **KPC-Producing**: Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are preferred options.
- **NDM-Producing (Metallo-beta-lactamase)**: Combination of ceftazidime-avibactam + aztreonam OR cefiderocol are preferred.

### Difficult-to-Treat (DTR) Pseudomonas aeruginosa
- **Preferred Agents**: Newer beta-lactam/beta-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam, or imipenem-relebactam) are preferred over older agents (e.g., aminoglycosides or polymyxins) for serious infections.

### Carbapenem-Resistant Acinetobacter baumannii (CRAB)
- **Combination Therapy**: Recommended for serious infections, typically involving high-dose ampicillin-sulbactam (as a part of a regimen) or cefiderocol.
- **Sulbactam-Durlobactam**: A preferred new option for CRAB infections.

### Stenotrophomonas maltophilia
- **Preferred Agents**: Combination therapy is often recommended for serious infections; options include trimethoprim-sulfamethoxazole, minocycline, or cefiderocol.

### Stewardship and Monitoring
- **Molecular Testing**: Recommends the use of rapid molecular diagnostic tests for early detection of resistance mechanisms (e.g., *bla*KPC, *bla*NDM) to guide specific therapy.
- **PK/PD**: Emphasizes the use of optimized dosing (e.g., extended infusions) for beta-lactams to maximize efficacy against resistant pathogens.
